A randomized, open-label, crossover study examiningthe effect of injection site on bioavailability of exenatide (synthetic exendin-4)
- 28 February 2005
- journal article
- clinical trial
- Published by Elsevier BV in Clinical Therapeutics
- Vol. 27 (2), 210-215
- https://doi.org/10.1016/j.clinthera.2005.02.008
Abstract
No abstract availableKeywords
This publication has 23 references indexed in Scilit:
- Synthetic Exendin-4 (Exenatide) Significantly Reduces Postprandial and Fasting Plasma Glucose in Subjects with Type 2 DiabetesJournal of Clinical Endocrinology & Metabolism, 2003
- Therapy of type 2 diabetes mellitus based on the actions of glucagon-like peptide-1Diabetes/Metabolism Research and Reviews, 2002
- Insulinotropic Hormone Glucagon-Like Peptide-1 Differentiation of Human Pancreatic Islet-Derived Progenitor Cells into Insulin-Producing CellsEndocrinology, 2002
- Effect of 6-week course of glucagon-like peptide 1 on glycaemic control, insulin sensitivity, and β-cell function in type 2 diabetes: a parallel-group studyThe Lancet, 2002
- The Insulinotropic Effect of Acute Exendin-4 Administered to Humans: Comparison of Nondiabetic State to Type 2 DiabetesJournal of Clinical Endocrinology & Metabolism, 2002
- Insulinotropic actions of exendin-4 and glucagon-like peptide-1 in vivo and in vitroMetabolism, 2001
- Exendin-4 stimulates both beta-cell replication and neogenesis, resulting in increased beta-cell mass and improved glucose tolerance in diabetic rats.Diabetes, 1999
- Glucagon-like peptide 1 and exendin-4 convert pancreatic AR42J cells into glucagon- and insulin-producing cells.Diabetes, 1999
- Glucose-lowering and insulin-sensitizing actions of exendin-4: studies in obese diabetic (ob/ob, db/db) mice, diabetic fatty Zucker rats, and diabetic rhesus monkeys (Macaca mulatta).Diabetes, 1999
- Normalization of fasting hyperglycaemia by exogenous glucagon-like peptide 1 (7-36 amide) in Type 2 (non-insulin-dependent) diabetic patientsDiabetologia, 1993